News
AKBA
1.830
+2.23%
0.040
Ardelyx: A Small Bet Its Latest Setback Will Be Temporary
Seeking Alpha · 2d ago
Weekly Report: what happened at AKBA last week (1209-1213)?
Weekly Report · 12/16 10:41
Weekly Report: what happened at AKBA last week (1202-1206)?
Weekly Report · 12/09 10:40
New Strong Sell Stocks for December 5th
NASDAQ · 12/05 10:46
Akebia: U.S. Renal Care enrolls first patient in its VOICE collaborative trial
TipRanks · 12/03 12:11
Akebia Therapeutics And U.S. Renal Care Enroll First Patient In Vafseo Outcomes VOICE Trial
Benzinga · 12/03 12:05
AKEBIA THERAPEUTICS INC - VAFSEO EXPECTED TO BE AVAILABLE IN U.S. IN JANUARY 2025
Reuters · 12/03 12:00
U.S. RENAL CARE ENROLLED FIRST PATIENTS IN THE VOICE COLLABORATIVE CLINICAL TRIAL OF VAFSEO® (VADADUSTAT) FOR CKD PATIENTS ON DIALYSIS
Reuters · 12/03 12:00
Weekly Report: what happened at AKBA last week (1125-1129)?
Weekly Report · 12/02 10:40
Biotech Alert: Searches spiking for these stocks today
TipRanks · 11/29 16:15
New Strong Sell Stocks for November 27th
NASDAQ · 11/27 09:42
Weekly Report: what happened at AKBA last week (1118-1122)?
Weekly Report · 11/25 10:34
New Strong Sell Stocks for November 22nd
NASDAQ · 11/22 08:53
Q3 2024 Earnings: Hold Akebia Therapeutics
Seeking Alpha · 11/20 20:31
Weekly Report: what happened at AKBA last week (1111-1115)?
Weekly Report · 11/18 10:32
Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In Hemodialysis Patients Who Were Converted From A Long-Acting Erythropoiesis-stimulating Agent To 3-Times Weekly Oral Vadadustat Dosing For The Maintenance Treatment Of Anemia
Benzinga · 11/14 13:26
Weekly Report: what happened at AKBA last week (1104-1108)?
Weekly Report · 11/11 10:41
Akebia Therapeutics Prepares for Vafseo Launch
TipRanks · 11/08 05:31
Akebia Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/07 14:15
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 11/07 13:15
More
Webull provides a variety of real-time AKBA stock news. You can receive the latest news about Akebia Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.